It is fascinating what has happened in the last couple of years in the animal health industry, which runs to $22 billion a year for animal drugs and vaccines and is expected to grow at 5.7% compound annual rate, faster than the market for human medicines.
Zoetis ($ZTS) was spun off from Pfizer ($PFE) as the largest independent animal health company. M&A action in recent months is remixing the players once again. Next year, Novartis ($NVS) will be off of this list, and based on current revenues, Eli Lilly's ($LLY) Elanco should ascend to the number two position.
Many, but not all, of the largest are units of Big Pharma. One of the things you might notice is the range in size from largest to smallest, $4.56 billion, to $413 million. Given the current M&A atmosphere, there is a good chance that another player could be spun off, or sold, reshuffling the deck once again.
With all of the changes, it is good to set a benchmark, mark a place by which the ongoing changes can be measured. So here is ours, thanks to data provided by Brakke Consulting based on 2013 revenues.
Read it over and if you have thoughts, let me or our associate editor, Justin Heifetz, know.